<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054587</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0140/0005 - PACS 04</org_study_id>
    <secondary_id>FRE-FNCLCC-PACS-04/0005</secondary_id>
    <secondary_id>EU-20236</secondary_id>
    <secondary_id>PACS04</secondary_id>
    <nct_id>NCT00054587</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer</brief_title>
  <official_title>Randomized And Multicentric Opened Phase III Study Evaluating The Concomitant Administration Of Docetaxel 75MG/M2 and Epirubicine 75MG/M2 Versus FEC 100 In Non Metastatic With Positive Lymphatic Nodes Breast Cancer Subjects, And The Sequential Addition Of Herceptin In (HER2+++) And (HER2++ And FISH+) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells
      and either kill them or deliver tumor-killing substances to them without harming normal
      cells. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known
      which regimen of chemotherapy plus radiation therapy with or without trastuzumab is more
      effective in treating breast cancer.

      PURPOSE: Randomized phase III trial to compare two different chemotherapy regimens plus
      radiation therapy with or without trastuzumab in treating women who have breast cancer that
      has spread to lymph nodes in the axilla (under the arm).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of adjuvant cyclophosphamide, epirubicin, and fluorouracil vs
           adjuvant docetaxel and epirubicin, in terms of 5-year survival without relapse, in women
           with nonmetastatic adenocarcinoma of the breast with lymph node invasion.

        -  Determine survival of patients treated with these regimens.

        -  Compare the tolerability of trastuzumab (Herceptin) in patients treated with these
           regimens.

        -  Determine the efficacy and tolerability of trastuzumab in patients with hormone
           receptor-positive tumors.

        -  Evaluate the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
      according to participating center. Patients are treated in 2 parts.

        -  Part I: Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive fluorouracil IV, or epirubicin IV, and cyclophosphamide IV
                on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo
                radiotherapy 5 days a week for 5 weeks.

             -  Arm II: Patients receive epirubicin IV over 10 minutes and docetaxel IV over 1 hour
                on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo
                radiotherapy as in arm I.

      Patients with HER2/neu-positive tumors then proceed to part II. Patients with
      HER2/neu-negative tumors receive no further treatment.

      Patients with hormone (estrogen or progesterone) receptor-positive tumors also receive oral
      tamoxifen daily beginning after chemotherapy is completed and continuing for 5 years.

        -  Part II: Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive trastuzumab (Herceptin) IV over 30-90 minutes every 3 weeks
                for 1 year.

             -  Arm II: Patients are followed without treatment. Patients not receiving trastuzumab
                are followed at 4 months, 6 months, every 4 months for 1 year, and then every 6
                months for 3 years. Patients receiving trastuzumab are followed at 4 months and
                then every 6 months for 3 years.

      PROJECTED ACCRUAL: A total of 2,600 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years from randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Herceptin safety</measure>
    <time_frame>5 years from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3010</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>6 FEC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive fluorouracil IV, or epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy 5 days a week for 5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 DE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive epirubicin IV over 10 minutes and docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy as in arm I</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)</description>
    <arm_group_label>6 FEC</arm_group_label>
    <arm_group_label>6 DE</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>500 mg/m², D1 and every 3 weeks</description>
    <arm_group_label>6 FEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks</description>
    <arm_group_label>6 DE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>100 mg/m², D1 and every 3 weeks</description>
    <arm_group_label>6 FEC</arm_group_label>
    <arm_group_label>6 DE</arm_group_label>
    <other_name>epirubicin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>500 mg/m², D1 and every 3 weeks</description>
    <arm_group_label>6 FEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed nonmetastatic, unilateral adenocarcinoma of the breast

               -  Axillary lymph node invasion (N1, N2, or N3)

               -  No cutaneous invasion

               -  No T4a or greater disease

          -  No clinically or radiologically suspected metastases

          -  No clinically or radiologically suspected contralateral lesion

          -  No deeply adherent or inflammatory disease

          -  Complete surgical resection performed, including removal of at least 5 lymph nodes,
             and with no residual tumor, within the past 42 days

          -  No prior breast cancer

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 64

        Sex

          -  Female

        Menopausal status

          -  Not specified

        Performance status

          -  WHO 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  ALT and AST no greater than 1.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase no greater than 2.5 times ULN

          -  Bilirubin no greater than ULN

          -  Hepatitis B and hepatitis C negative

          -  No hepatic dysfunction

        Renal

          -  Creatinine less than 1.3 mg/dL OR

          -  Creatinine clearance greater than 60 mL/min

        Cardiovascular

          -  ECHO normal

          -  LVEF at least 50%

        Pulmonary

          -  FEV normal

          -  No dyspnea at rest

          -  No supplemental oxygen dependence

        Other

          -  Not pregnant

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No active infection

          -  No other prior malignancy except basal cell skin cancer or carcinoma in situ of the
             cervix

          -  No contraindication to anthracycline therapy

          -  No chronic medical or psychological condition

          -  No geographic or social reason that would preclude study therapy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  At least 4 weeks since prior chemotherapy

          -  No other concurrent chemotherapy

          -  No contraindication to anthracycline therapy

        Endocrine therapy

          -  No prior hormonal therapy

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  See Disease Characteristics

        Other

          -  At least 4 weeks since prior experimental therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Spielmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74011 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Bourg En Bresse</name>
      <address>
        <city>Bourg En Bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Intercommunal De Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Prive de Cancerologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Petit Colmouilins</name>
      <address>
        <city>Harfleur</city>
        <zip>76700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lagny</name>
      <address>
        <city>Lagny Sur Marne</city>
        <zip>77405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMC Les Ormeaux</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Metz Thionville</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General Andre Boulloche</name>
      <address>
        <city>Montbeliard</city>
        <zip>25209</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68051</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint - Pierre</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Clotilde</name>
      <address>
        <city>Sainte Clotilde</city>
        <zip>97492</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Mancini J, Genre D, Dalenc F, Maylevin F, Martin AL, Viens P, Julian-Reynier C. Transparency in the presentation of trial results may not increase patients' trust in medical researchers. Clin Trials. 2012 Feb;9(1):90-3. doi: 10.1177/1740774511427063. Epub 2011 Nov 2.</citation>
    <PMID>22049088</PMID>
  </reference>
  <results_reference>
    <citation>Roché H, Allouache D, Romieu G, et al.: Five-year analysis of the FNCLCC-PACS04 trial: FEC100 vs ED75 for the adjuvant treatment of node positive breast cancer. [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-602, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009 Dec 20;27(36):6129-34. doi: 10.1200/JCO.2009.23.0946. Epub 2009 Nov 16.</citation>
    <PMID>19917839</PMID>
  </results_reference>
  <results_reference>
    <citation>Spielmann M, Roché H, Humblet Y, et al.: 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial. [Abstract] Breast Cancer Res Treat 106 (1): A-72, S19, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Spielmann M, Roché H, Delozier T, et al.: Safety analysis from PACS 04--a phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+patients: preliminary results. [Abstract] J Clin Oncol 24 (Suppl 18): A-632, 2006.</citation>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>July 18, 2013</last_update_submitted>
  <last_update_submitted_qc>July 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

